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A bs tr ac t
Background
We compared docetaxel with vinorelbine for the adjuvant treatment of early breast 
cancer. Women with tumors that overexpressed HER2/neu were also assigned to 
receive concomitant treatment with trastuzumab or no such treatment.
Methods
We randomly assigned 1010 women with axillary-node–positive or high-risk node-
negative cancer to receive three cycles of docetaxel or vinorelbine, followed by (in 
both groups) three cycles of fluorouracil, epirubicin, and cyclophosphamide. The 
232 women whose tumors had an amplified HER2/neu gene were further assigned 
to receive or not to receive nine weekly trastuzumab infusions. The primary end 
point was recurrence-free survival.
Results
Recurrence-free survival at three years was better with docetaxel than with vinorel-
bine (91 percent vs. 86 percent; hazard ratio for recurrence or death, 0.58; 95 percent 
confidence interval, 0.40 to 0.85; P = 0.005), but overall survival did not differ between 
the groups (P = 0.15). Within the subgroup of patients who had HER2/neu-positive 
cancer, those who received trastuzumab had better three-year recurrence-free sur-
vival than those who did not receive the antibody (89 percent vs. 78 percent; hazard 
ratio for recurrence or death, 0.42; 95 percent confidence interval, 0.21 to 0.83; 
P = 0.01). Docetaxel was associated with more adverse effects than was vinorelbine. 
Trastuzumab was not associated with decreased left ventricular ejection fraction or 
cardiac failure.
Conclusions
Adjuvant treatment with docetaxel, as compared with vinorelbine, improves recur-
rence-free survival in women with early breast cancer. A short course of trastuzumab 
administered concomitantly with docetaxel or vinorelbine is effective in women with 
breast cancer who have an amplified HER2/neu gene. (International Standard Ran-
domised Controlled Trial number, ISRCTN76560285.)
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Adjuvant (postoperative) treatment has markedly reduced rates of death due to breast cancer.1,2 However, in 15 to 25 per-
cent of breast carcinomas, there is amplification 
of the HER2/neu (ErbB2) gene, an excess of the 
HER2 protein in the cancer cells,3 and a high risk 
of recurrence.4-6
Trastuzumab (Herceptin, Roche) is a human-
ized monoclonal antibody against the HER2 pro-
tein. When administered with chemotherapy, it 
improves survival in advanced HER2-positive breast 
cancer.7,8 When given concomitantly with pacli-
taxel or after chemotherapy for 12 months as ad-
juvant treatment for early HER2-positive breast 
cancer, trastuzumab reduces the risk of recurrence 
by approximately 50 percent and the risk of death 
by approximately 30 percent.9,10 In these studies, 
the principal adverse event attributable to trastu-
zumab was heart failure, which occurred in 1.7 
to 4.1 percent of women treated with the anti-
body; approximately 10 percent of trastuzumab-
treated participants had a substantial decrease 
in the left ventricular ejection fraction. The risk 
of cardiac dysfunction with trastuzumab treat-
ment increases with the use of anthracyclines.7,11 
The long-term outcome of trastuzumab-related 
heart failure is unknown, although symptoms 
usually subside with cessation of treatment with 
trastuzumab and management of the condition.10
Combining trastuzumab with docetaxel, vino-
relbine, cisplatin, carboplatin, or paclitaxel has 
resulted in the highest pooled response rates to 
date in the treatment of breast cancer.12 Data 
obtained in vitro suggest that such combinations 
kill breast cancer cells by synergistic effects.13,14 
In the FinHer (Finland Herceptin) study, we com-
pared docetaxel with vinorelbine, administered 
with or without trastuzumab, as adjuvant treat-
ment for early breast cancer. In this study, trastu-
zumab was administered before other cardiotoxic 
therapies and concomitantly with potentially 
synergistic chemotherapy for only nine weeks to 
test the hypothesis that such a schedule would 
limit cardiotoxicity and maintain efficacy.
Me thods
Study Population
Women eligible for the study were less than 66 
years of age, had a World Health Organization 
performance status of 0 or 1, and had undergone 
breast surgery with axillary-node dissection or 
sentinel-node biopsy for invasive breast carcinoma. 
We required determination of steroid hormone–
receptor status and HER2 expression by immuno-
histochemistry, according to the guidelines of each 
institution. When HER2 expression was scored 
2+ or 3+ (on a scale of 0, 1+, 2+, or 3+), the num-
ber of copies of the HER2/neu gene was determined 
by means of chromogenic in situ hybridization in 
one of two reference laboratories.15
Participants were randomly assigned (centrally 
and with computer-assisted blinding) to a study 
group within 12 weeks after surgery. Eligible pa-
tients had either at least one positive axillary node 
(regardless of the primary tumor size or its hor-
mone-receptor expression) or a node-negative 
breast-cancer mass at least 20 mm in diameter 
and a negative test for progesterone receptors 
(usually defined as staining of <10 percent of the 
cancer cells). The staging workup included iso-
tope bone scanning; chest radiography or com-
puted tomography (CT); and CT or ultrasonog-
raphy of the upper abdomen.
Criteria for exclusion were distant metastases, 
pregnancy, severe hypertension, and cardiac dis-
ease (including cardiac failure of any degree, ar-
rhythmia requiring regular medication, and myo-
cardial infarction within the previous 12 months). 
Patients were ineligible if they had a serum bili-
rubin level above the upper limit of normal, an 
alanine or aspartate aminotransferase level greater 
than 1.5 times the upper limit of normal, an alka-
line phosphatase level above 2.5 times the upper 
limit of normal, a blood leukocyte count below 
3.0×109 per milliliter, a neutrophil count below 
1.5×109 per milliliter, or a platelet count be-
low 120×109 per milliliter.
An ethics committee at Helsinki University 
Central Hospital approved the study. Study par-
ticipants provided written informed consent.
Study Design
Figure 1 shows the design of the trial. Random-
ization was stratified according to HER2 status 
(positive vs. negative) and institution in this 
phase 3, open-label, multicenter trial. Permuted 
blocks were used to randomly assign all partici-
pants to receive three cycles of either docetaxel or 
vinorelbine. Docetaxel (Taxotere, Sanofi-Aventis) 
was given at a dose of 100 mg per square meter 
of body-surface area as a one-hour intravenous in-
fusion on day 1 of each 21-day cycle. Vinorelbine 
(Navelbine, Pierre Fabre) was administered at a 
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dose of 25 mg per square meter as a 5-to-10-minute 
intravenous infusion on days 1, 8, and 15 of the 
21-day cycles. After the completion of docetaxel 
or vinorelbine treatment, three cycles of a regimen 
consisting of intravenous fluorouracil at a dose 
of 600 mg per square meter, epirubicin at a dose 
of 60 mg per square meter, and cyclophospha-
mide at a dose of 600 mg per square meter, each 
administered on day 1 of a 21-day cycle (FEC), 
were given. The vinorelbine infusion on day 15 
was omitted from the third cycle to allow the 
initiation of FEC at a full dose without delay. The 
duration of the chemotherapy regimen was 18 
weeks.
Women who had verified HER2-positive cancer 
were randomly assigned to receive or not to re-
ceive trastuzumab. Nine trastuzumab infusions 
were administered at one-week intervals; the first 
infusion was given on day 1 of the first docetaxel 
or vinorelbine cycle. The first dose was 4 mg per 
kilogram of body weight and the subsequent 
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Local determination of HER2/neu expression by immunohistochemistry
Randomization (N=1010)
Confirmation of HER2/neu amplification by CISH in one of two labora-































Follow-up (median, 36 mo; range, 20–55 mo)
27 Recurrences
or deaths
Figure 1. The Design of the Trial.
CISH denotes chromogenic in situ hybridization, and FEC a regimen of fluorouracil, epirubicin, and cyclophosphamide.
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riods of 90 and 30 minutes, respectively. Trastu-
zumab was infused before docetaxel or vinorel-
bine. No trastuzumab was given during FEC 
administration.
The primary end point was recurrence-free 
survival, defined as the time from the date of ran-
domization to the date of detection (with histo-
logic or cytologic confirmation or with radio-
logic evidence) of local, distant, or contralateral 
invasive breast cancer or death, whichever oc-
curred first. Secondary end points included ad-
verse effects, the effect of treatment on the left 
ventricular ejection fraction, the time to distant 
recurrence, and overall survival, defined as time 
from randomization to death from any cause.
Study Procedures
Concomitant Therapy
Patients assigned to docetaxel received six 7.5-mg 
doses of dexamethasone; the first two were given 
12 hours and 1 hour before docetaxel infusion 
and the rest at 12-hour intervals after infusion. 
Use of prophylactic antibiotics or granulocyte 
colony-stimulating factors was not recommended 
unless one or more episodes of febrile neutrope-
nia or severe infection occurred.
Radiotherapy was given after the completion 
of chemotherapy according to each institution’s 
guidelines, but it was required after breast-con-
serving surgery. Tamoxifen at a dose of 20 mg per 
day was administered to patients with estrogen-
receptor–positive or progesterone-receptor–posi-
tive tumors; this treatment was to be continued 
for five years.
Dose Modifications
Chemotherapy doses were reduced by 20 percent 
in cases of persistent hematologic toxic effects or 
grade 3 or 4 nonhematologic toxic effects, defined 
according to the National Cancer Institute Com-
mon Toxicity Criteria (version 2.0). When either 
docetaxel or vinorelbine was discontinued because 
of adverse effects, the cycles not given were re-
placed by an equal number of cycles of FEC. 
Trastuzumab was administered at full doses re-
gardless of blood-cell counts, but infusions were 
deferred whenever vinorelbine or docetaxel infu-
sions were postponed because of adverse effects.
Evaluations
Adverse effects of therapy were recorded on proto-
col-specified forms on day 21 of each chemother-
apy cycle and 12 and 36 months after chemo-
therapy. Patients were scheduled for follow-up 
for a minimum of five years. Mammography was 
performed at one-to-two-year intervals, but other-
wise follow-up was carried out according to each 
institution’s guidelines. In the group of patients 
assigned to trastuzumab treatment, the left ven-
tricular ejection fraction was measured by either 
echocardiography or isotope cardiography before 
chemotherapy, after the last FEC cycle, and 12 
and 36 months after chemotherapy.
Statistical Analysis
The study was designed to have a power of 0.80 
to detect an increase in five-year recurrence-free 
survival from 70 percent to 80 percent in the 
docetaxel-plus-FEC group as compared with the 
vinorelbine-plus-FEC group (with use of a two-
sided test at a significance level of 0.05); approx-
imately 150 events were required for this purpose. 
We estimated that 30 percent of the participants 
would have breast cancer with HER2/neu amplifi-
cation and that the study would be able to detect 
a difference in their five-year recurrence-free sur-
vival of 50 percent to 67 percent at a power of 
0.80 when approximately 1000 patients were en-
rolled.
Protocol-defined safety analyses took place 
in March 2001, September 2001, and December 
2002.16 The current protocol specified that safety 
and early efficacy analyses were to be carried out 
when the median follow-up time exceeded three 
years; this point was reached in May 2005. The 
final analyses will be performed when 150 events 
have occurred or the median follow-up time ex-
ceeds five years. For the primary variable, a P value 
of less than 0.029 was considered to indicate sig-
nificance, in order to maintain an overall type 1 
error of 0.05 for the interim and final analysis.17
Frequency tables were analyzed with use of 
the chi-square test. Survival between groups was 
compared with use of the Kaplan–Meier life-table 
method and the Cox proportional-hazards model; 
the log-rank test was used to confirm the robust-
ness of the analysis. Efficacy analyses were based 
on the intention-to-treat principle. The effects of 
treatment, time, the method of assessment, and 
their interactions with the left ventricular ejection 
fraction were analyzed in a repeated-measures 
analysis of covariance (ANCOVA) model; pretreat-
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ment measurement of the ejection fraction was 
used as a covariate and the ejection fractions 
measured later as response variables. All P values 
are two-sided and were not adjusted for multiple 
testing.
Dr. Joensuu drafted the study design. The in-
vestigators initiated the study, and collected, ana-
lyzed, and maintained the data. The sponsor (the 
Finnish Breast Cancer Group) received grants 
from Sanofi-Aventis, Pierre Fabre, and Pharmacia; 
Roche supported the HER2/neu analyses. Trastu-
zumab was purchased from funds provided in 
the state budget of Finland; other study drugs 
were purchased by the participating institutions. 
The manuscript was drafted by Dr. Joensuu and 
modified by the coauthors. The authors deter-
mined the content of the manuscript and vouch 
for its accuracy and completeness.
R esult s
Patients
From October 2000 to September 2003, 1010 
women (approximately 40 percent of the eligible 
women in Finland who received a diagnosis of 
breast cancer within this period, according to 
the Finnish Cancer Registry and other sources 
[www.cancer.fi])18 were randomly assigned to re-
ceive either docetaxel (502 women) or vinorelbine 
(508). Of these 1010 women, 232 who had an 
amplified HER2/neu gene were further randomly 
assigned to receive trastuzumab (116 women) or 
not to receive it (116). The median follow-up times 
were 36 and 35 months in the docetaxel and 
vinorelbine groups, respectively, and 37 and 35 
months in the trastuzumab and no-trastuzumab 
(control) groups, respectively, at the time of analy-
sis (May 19, 2005). No patient was lost to follow-
up. Two women who did not receive the study 
treatments because of abnormal results on liver-
function tests were excluded from the safety analy-
ses, and one woman (who had been assigned to 
the vinorelbine group and had HER2/neu-positive 
cancer) with overt distant metastases at random-
ization was excluded from the survival analyses. 
One woman with HER2/neu amplification did not 
participate in randomization with respect to trastu-
zumab, and seven women were ineligible. The 
baseline characteristics of the groups were bal-
anced, except that larger tumors were more com-
mon in the docetaxel group than in the vinorel-
bine group and axillary nodal metastases tended 
to be more frequent in the trastuzumab group 
than in the group that did not receive the anti-
body (Table 1).
Most (84.3 percent) of the cancers with strong 
(3+) HER2-protein expression on immunohisto-
chemical analysis contained amplified HER2/neu. 
Of the cancers that stained moderately positively 
(2+), 26.2 percent contained amplified HER2/neu.
Treatment
In February 2002, an independent study-monitor-
ing committee recommended that the dose of 
docetaxel be reduced because 36.9 percent of the 
women treated with this agent had received a 
diagnosis of neutropenic fever. Therefore, 206 of 
the 502 patients treated with docetaxel (41.0 per-
cent) received 100 mg per square meter and 296 
(59.0 percent) received 80 mg per square meter as 
the starting dose. Three docetaxel cycles were com-
pleted by 472 patients (94.0 percent), and three 
vinorelbine cycles were completed by 483 patients 
(95.1 percent). Docetaxel (100 mg per square 
meter), docetaxel (80 mg per square meter), and 
vinorelbine were given at the protocol-specified 
dose in 64.7, 83.9, and 82.4 percent of cycles, re-
spectively. The most common reasons for a reduc-
tion in the dose of docetaxel were neutropenia 
and neutropenic infections, and the most com-
mon reason for a reduction in the dose of vinorel-
bine was neutropenia. The full dose of trastuzu-
mab was administered in 99.1 percent of cycles, 
and 93.6 and 96.6 percent of the protocol-specified 
trastuzumab infusions were delivered to women 
in the docetaxel and vinorelbine groups, respec-
tively.
Three or more FEC cycles were administered 
to 98.6 and 98.0 percent of the women assigned 
to docetaxel and vinorelbine, respectively, and 91.2 
and 93.1 percent received FEC at the protocol-
specified dose. Adjuvant radiotherapy was given 
to 97.0 and 97.6 percent of the patients, respec-
tively, and tamoxifen to 71.1 and 73.8 percent.
Within the subgroup of women with HER2/neu-
positive cancer, 54 of the women assigned to re-
ceive trastuzumab (46.6 percent) and 58 of those 
who did not receive trastuzumab (50.0 percent) 
were in the docetaxel group (P = 0.60). The pro-
tocol-specified 100-mg dose of docetaxel was 
administered in 61.1 percent and 64.4 percent of 
the cycles in the trastuzumab and control groups, 
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respectively; the protocol-specified 80-mg dose 
of docetaxel in 83.3 percent and 81.6 percent of 
the cycles, respectively; the protocol-specified dose 
of vinorelbine in 80.3 percent and 71.9 percent 
of the cycles, respectively; and the protocol-speci-
fied dose of epirubicin in 94.0 percent and 92.0 
percent of the cycles, respectively.
Efficacy
Recurrence of breast cancer or death without re-
Table 1. Characteristics of the Patients and the Tumors at Baseline.*













WHO performance status — no. (%) 0.57 0.64
0 455 (91) 455 (90) 105 (91) 107 (92)
1 47 (9) 53 (10) 11 (9) 9 (8) 
No. of metastatic axillary nodes — no. (%) 0.73 0.06
0 57 (11) 54 (11) 12 (10) 25 (22)
1–3 300 (60) 316 (62) 64 (55) 58 (50)
>3 145 (29) 138 (27) 40 (34) 33 (28) 
Diameter of primary tumor — no. (%) 0.02 0.24
≤10 mm 30 (6) 52 (10) 8 (7) 8 (7)
11–20 mm 174 (35) 185 (36) 38 (33) 27 (23)
>20 mm 296 (59) 269 (53) 69 (59) 81 (70)
Not available 2 (<1) 2 (<1) 1 (1) 0
Histologic type — no. (%) 0.96† 0.51†
Ductal 390 (78) 398 (78) 106 (91) 103 (89)
Lobular 99 (20) 98 (19) 10 (9) 11(9)
Other 13 (3) 12 (2) 0 (0) 2 (2)
Histologic grade — no. (%) 0.39‡ 0.51‡
1 76 (15) 74 (15) 2 (2) 3 (3)
2 186 (37) 211 (42) 39 (34) 33 (28)
3 214 (43) 201 (40) 73 (63) 77 (66)
Not available 26 (5) 22 (4) 2 (2) 3 (3)
Estrogen-receptor status — no. (%) 0.50 0.36
Positive 358 (71) 372 (73) 58 (50) 51 (44)
Negative 144 (29) 136 (27) 58 (50) 65 (56)
Progesterone-receptor status — no. (%) 0.35 0.13
Positive 283 (56) 301 (59) 45 (39) 34 (29)
Negative 219 (44) 207 (41) 71 (61) 82 (71)
HER2/neu amplification — no. (%) 0.67 1.00
Absent 389 (77) 388 (76) 0 0
Present 113 (23)§ 120 (24) 116 (100) 116 (100)
Age — yr
Median 50.8 51.0 0.72 51.4 49.9 0.19
Range 25.5–65.7 26.9–65.8 25.5–65.8 27.3–64.5
* Percentages may not total 100, because of rounding. WHO denotes World Health Organization.
† The P value is for the ductal type as compared with the lobular and other types.
‡ The P value is for grade 1 or 2 as compared with grade 3.
§ One woman who had a tumor with HER2/neu amplification did not participate in randomization for trastuzumab.
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currence was less common among women treat-
ed with docetaxel plus FEC than among those 
treated with vinorelbine plus FEC (42 of 502 vs. 
71 of 507; hazard ratio for recurrence or death, 
0.58; 95 percent confidence interval, 0.40 to 0.85; 
P = 0.005) (Fig. 2A). The development of distant 
metastases also was less common in the docetax-
el group (33, vs. 58 in the vinorelbine group; haz-
ard ratio, 0.56; 95 percent confidence interval, 
0.37 to 0.86; P = 0.008). The hazard ratios for re-
currence or death in the docetaxel group, as com-
pared with the vinorelbine group, remained sim-
ilar when adjusted according to center (0.58; 95 
percent confidence interval, 0.40 to 0.85) or ac-
cording to the number of positive nodes (0.57; 95 
percent confidence interval, 0.39 to 0.83). Overall 
survival was not significantly different between 
the groups (20 patients in the docetaxel group vs. 
30 in the vinorelbine group died; hazard ratio for 
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Figure 2. Effects of Single-Agent Docetaxel or Vinorelbine and of Trastuzumab on the Kaplan–Meier Estimates of Recurrence-free 
 Survival (Panels A and C) and Overall Survival (Panels B and D) among Women with Breast Cancer.
One-, two-, and three-year survival data are shown. Hazard ratios are for recurrence or death (Panel A) or for death (Panel B) in the 
docetaxel group as compared with the vinorelbine group and, among women with HER2/neu-positive cancer, for recurrence or death 
(Panel C) or for death (Panel D) in the group that received trastuzumab as compared with the group that did not receive trastuzumab. 
FEC denotes a regimen of fluorouracil, epirubicin, and cyclophosphamide, and CI confidence interval.
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the vinorelbine group, 0.66; 95 percent confi-
dence interval, 0.38 to 1.17; P = 0.15) (Fig. 2B).
Of the 115 patients in the trastuzumab group 
who were included in the analysis of efficacy, 12 
had a recurrence of breast cancer or died with-
out recurrence, whereas in the control group 
(116 patients), there were 27 such cases (hazard 
ratio for recurrence or death in the trastuzumab 
group, as compared with the control group, 0.42; 
95 percent confidence interval, 0.21 to 0.83; 
P = 0.01) (Fig. 2C). The hazard ratio remained 
similar when adjustment was made according to 
the type of chemotherapy given (0.41; 95 percent 
confidence interval, 0.21 to 0.82), center (0.42; 
95 percent confidence interval, 0.21 to 0.83), or 
the number of positive nodes (0.39; 95 percent 
confidence interval, 0.20 to 0.77). Women who 
received trastuzumab had fewer distant recur-
rences of cancer than did women who did not 
receive the antibody (8 vs. 26; hazard ratio, 0.29; 
95 percent confidence interval, 0.13 to 0.64; 
P = 0.002) (Fig. 3). In addition, their overall sur-
vival tended to be better (6 vs. 14 patients died; 
hazard ratio for death, 0.41; 95 percent confi-
dence interval, 0.16 to 1.08; P = 0.07) (Fig. 2D).
Adverse Effects
Docetaxel was more commonly associated with 
neutropenic fever, stomatitis, alopecia, nail prob-
lems, toxic effects on the skin, allergic reactions, 
neuropathy, and edema than was vinorelbine, 
which more frequently caused peripheral-vein 
phlebitis and elevation in the serum aspartate 
aminotransferase level. After the dose of docetax-
el was reduced from 100 mg per square meter to 
80 mg per square meter, the frequency of neutro-
penic fever decreased to 14.9 percent (P<0.001). 
Trastuzumab did not significantly increase the 
frequency of adverse events related to vinorelbine 
or docetaxel (Table 2).
One patient had cardiac infarction and three 
had cardiac failure; none of these four patients 
had received trastuzumab. Left ventricular ejection 
fractions were preserved in women who received 
trastuzumab (Table 3). Trastuzumab-treated 
women had slightly better ejection fractions than 
those who did not receive trastuzumab; in an 
ANCOVA model, the estimated difference 12 
months after the completion of chemotherapy 
was 1.7 percentage points (95 percent confidence 
interval, −0.1 to 3.5 percentage points; P = 0.06), 
and at 36 months it was 3.0 percentage points 
(0.7 to 5.4 percentage points, P = 0.01). In this 
model, vinorelbine and docetaxel had similar 
estimated effects on the ejection fraction at both 
times (P = 0.50). Four women treated with trastu-
zumab (3.5 percent) and seven who were not (6.0 
percent) had one or more measurements of ejec-
tion fraction more than 15 percentage points 


















































0 1 2 3 4
Years
A: HER2/neu+, trastuzumab
B: HER2/neu¡, no trastuzumab
C: HER2/neu+, no trastuzumab
100
B vs. C: hazard ratio, 0.31 (95% CI, 0.20–0.49, P<0.001)
A vs. C: hazard ratio, 0.29 (95% CI, 0.13–0.64, P=0.002)
A vs. B: hazard ratio, 1.09 (95% CI, 0.52–2.29, P=0.82)
Figure 3. Effect of HER2/neu Amplification and Trastuzumab on the Kaplan–Meier Estimates of Survival Free 
of a First Distant Recurrence of Breast Cancer.
CI denotes confidence interval.
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more than 10 percentage points, resulting in an 
ejection fraction of less than 50 percent, occurred 
in three patients (none of whom had received 
trastuzumab).
Discussion
Adjuvant docetaxel, as compared with vinorelbine, 
improved recurrence-free survival in women with 
breast cancer. However, docetaxel was more toxic, 
and the scheduled starting dose was reduced dur-
ing the study because of adverse effects. The use 
of granulocyte colony-stimulating factors or pro-
phylactic antibiotics might have reduced the sever-
ity of neutropenia. Different doses of docetaxel 
have not been compared in the adjuvant setting. 
In this trial, women treated with 100 mg of 
docetaxel per square meter and those treated with 
80 mg per square meter had similar outcomes 
(data not shown), but this unplanned analysis may 
have been underpowered.
A short course of adjuvant trastuzumab given 
concomitantly with chemotherapy, as compared 
with chemotherapy alone, was an effective treat-
ment for HER2/neu-positive cancer. None of the 
women who were treated with trastuzumab had 
cardiac failure, and unexpectedly, these women 
had slightly better maintenance of left ventricu-
lar ejection fraction than did those who did not 
receive the antibody. Administration of trastu-
zumab before FEC and radiotherapy as well as 
the small cumulative dose of epirubicin given 
may have contributed to the preservation of car-
diac function. Regimens containing more than 
60 mg of epirubicin per square meter per cycle 
may have better efficacy than smaller doses,19 but 
epirubicin at a dose of 90 mg per square meter, 
given for four to six cycles with cyclophospha-
mide and trastuzumab, may frequently decrease 
the left ventricular ejection fraction and occasion-
ally cause congestive heart failure.20
This prospective study confirms the adverse 
effect of HER2/neu amplification on prognosis. 
Survival free of distant disease was substantially 





At the Last 
Chemotherapy Cycle
12 Mo after 
Chemotherapy
36 Mo after 
Chemotherapy
Docetaxel plus FEC (N = 58)
LVEF (%)
Median 67 64 64 64
Range 53–83 48–78 45–79 52–76
No. of patients 56 51 49 24
Docetaxel plus FEC and trastuzumab (N = 54)
LVEF (%)
Median 66 65 66 69
Range 49–82 51–78 51–83 49–77
No. of patients 50 48 48 30
Vinorelbine plus FEC (N = 58)
LVEF (%)
Median 65 65 65 63
Range 50–80 46–80 45–78 44–74
No. of patients 53 49 48 22
Vinorelbine plus FEC and trastuzumab (N = 61)
LVEF (%)
Median 64  63 65 64
Range 47–85 47–85 45–79 53–80
No. of patients 61 60 60 32
* FEC denotes fluorouracil, epirubicin, and cyclophosphamide.
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less favorable among women with HER2/neu-posi-
tive cancer who did not receive trastuzumab than 
among those with HER2/neu-negative cancer (Fig. 
3). Trastuzumab abrogates much of the adverse 
effect of HER2/neu amplification on outcome.
The proportion of women with HER2/neu-
positive disease was 23 percent, and thus only 
232 women participated in randomization with 
respect to trastuzumab. The small size of this 
subgroup and the short duration of the follow-up 
are limitations of the study. Nevertheless, the 
number was large enough to allow detection of 
a statistically significant difference in recurrence-
free survival between treatments. When design-
ing the study, we anticipated that HER2/neu am-
plification would be associated with frequent 
relapses4-6 and that trastuzumab would be effec-
tive, according to findings in studies of its use in 
metastatic disease.7 The likelihood of detecting 
a difference was expected to be further improved 
by the use of in situ hybridization to determine 
the number of copies of HER2/neu during patient 
selection and by the concomitant use of poten-
tially synergistic chemotherapy.13,14
The optimal duration of adjuvant trastuzumab 
therapy is not known and may be clarified only 
in further randomized trials. Our results indicate 
that a nine-week period of trastuzumab admin-
istration is effective in women with HER2/neu-
positive breast cancer. Regimens in which only a 
few cycles of trastuzumab are administered con-
currently with chemotherapy reduce the number 
of patient visits and may be more cost-effective 
than regimens that require administration over 
a period of 12 to 24 months.9,10,21 In addition, 
such regimens may result in few cardiac adverse 
effects.
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